TILs Therapy for NSCLC (Non‑Small Cell Lung Cancer)

Tumor‑Infiltrating Lymphocyte (TIL) therapy for NSCLC is an advanced immunotherapeutic approach in which a patient’s own tumor‑residing lymphocytes are harvested, expanded ex vivo with IL‑2, and reinfused after lymphodepletion (cyclophosphamide + fludarabine), often followed by maintenance checkpoint inhibitors like nivolumab. Phase I/II trials show objective response rates of ~21–25%, including durable complete responses in heavily pretreated patients-even those with low PD‑L1 expression or EGFR mutations. Responses have lasted beyond 6–18 months in some cases. While clinical use remains investigational for NSCLC, early results support its viability in metastatic, immune‑resistant disease with high mutational burden. Positioned within Luxora’s oncology sequence as a cutting‑edge, high‑impact intervention reserved for advanced or checkpoint‑refractory lung cancers.